Why the study?
Radiotherapy-associated angiosarcoma (RAAS) is reported as a rare, but serious late complication of radiotherapy for breast cancer, but detailed data on its incidence, latency, and outcomes were needed.
Answers are grounded in this paper and cite their sources.
RAAS incidence after breast RT informs counseling; leaves open optimal prevention and management strategies.
Radiotherapy-associated angiosarcoma (RAAS) has been reported as a rare, but serious late complication of radiotherapy (RT) for breast cancer. This study describes the incidence, latency period, and outcomes of RAAS using the prospective database from the nationwide Netherlands Cancer Registry.
No takes yet. Share an insight, caveat, or question.
Rombouts et al. (2019) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: